✦ LIBER ✦

A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer

✍ Scribed by Giannis Mountzios, Kostas N. Syrigos

Book ID: 119931065
Publisher: Springer International Publishing AG
Year: 2011
Tongue: English
Weight: 141 KB
Volume: 34
Category: Article
ISSN: 0114-5916
DOI: 10.2165/11586540-000000000-00000

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib in Previously Treated Non–Smal

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

✍ Shepherd, Frances A.; Rodrigues Pereira, José; Ciuleanu, Tudor; Tan, Eng Huat; H 📂 Article 📅 2005 🏛 Massachusetts Medical Society 🌐 English ⚖ 269 KB

19 Erlotinib in the treatment of non-sma

19 Erlotinib in the treatment of non-small-cell lung cancer

✍ Kyte, J.; Wilson, P.C.; Dangoor, A. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Reviewing the safety of erlotinib in non

Reviewing the safety of erlotinib in non-small cell lung cancer

✍ Reck, Martin; Mok, Tony; Wolf, Jürgen; Heigener, David; Wu, Yi-long 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 383 KB

Role of Erlotinib in the Treatment of No

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

✍ Piperdi, Bilal; Perez-Soler, Roman 📂 Article 📅 2012 🏛 Springer International Publishing AG 🌐 English ⚖ 168 KB

Risk-benefit relationships in cancer cli

Risk-benefit relationships in cancer clinical trials: The ECOG experience in non-small-cell lung cancer

📂 Article 📅 1985 🏛 Elsevier Science 🌐 English ⚖ 114 KB

Emerging Role of Erlotinib (OSI-774) in

Emerging Role of Erlotinib (OSI-774) in Non–Small-Cell Lung Cancer

✍ Chandra P. Belani 📂 Article 📅 2004 🏛 CIG Media Group, LP. 🌐 English ⚖ 53 KB